RS67767B1 - Kombinacija koja obuhvata mek inhibitor i b-raf inhibitor - Google Patents

Kombinacija koja obuhvata mek inhibitor i b-raf inhibitor

Info

Publication number
RS67767B1
RS67767B1 RS20260205A RSP20260205A RS67767B1 RS 67767 B1 RS67767 B1 RS 67767B1 RS 20260205 A RS20260205 A RS 20260205A RS P20260205 A RSP20260205 A RS P20260205A RS 67767 B1 RS67767 B1 RS 67767B1
Authority
RS
Serbia
Prior art keywords
inhibitor
combination
raf
mek
mek inhibitor
Prior art date
Application number
RS20260205A
Other languages
English (en)
Inventor
Melissa Dumble
Rakesh Kumar
Sylvie Laquerre
Peter Lebowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS67767(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS67767B1 publication Critical patent/RS67767B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
RS20260205A 2009-10-16 2010-10-15 Kombinacija koja obuhvata mek inhibitor i b-raf inhibitor RS67767B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16
EP24175377.1A EP4397376B1 (en) 2009-10-16 2010-10-15 Combination comprising an mek inhibitor and a b-raf inhibitor

Publications (1)

Publication Number Publication Date
RS67767B1 true RS67767B1 (sr) 2026-03-31

Family

ID=43876568

Family Applications (4)

Application Number Title Priority Date Filing Date
RSP20191095 RS59181B1 (sr) 2009-10-16 2010-10-15 Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
RS20240873A RS65800B1 (sr) 2009-10-16 2010-10-15 Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
RS20220984A RS63702B1 (sr) 2009-10-16 2010-10-15 Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
RS20260205A RS67767B1 (sr) 2009-10-16 2010-10-15 Kombinacija koja obuhvata mek inhibitor i b-raf inhibitor

Family Applications Before (3)

Application Number Title Priority Date Filing Date
RSP20191095 RS59181B1 (sr) 2009-10-16 2010-10-15 Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
RS20240873A RS65800B1 (sr) 2009-10-16 2010-10-15 Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
RS20220984A RS63702B1 (sr) 2009-10-16 2010-10-15 Kombinacija koja sadrži inhibitor mek i inhibitor b-raf

Country Status (35)

Country Link
US (3) US8703781B2 (sr)
EP (5) EP4706770A2 (sr)
JP (1) JP5718929B2 (sr)
KR (1) KR101729116B1 (sr)
CN (1) CN102655753B (sr)
AU (1) AU2010306653B2 (sr)
BR (1) BR112012008854B8 (sr)
CA (1) CA2775803C (sr)
CL (1) CL2012000964A1 (sr)
CO (1) CO6531498A2 (sr)
CR (1) CR20120155A (sr)
CY (1) CY1122013T1 (sr)
DK (4) DK4397376T3 (sr)
DO (1) DOP2012000091A (sr)
EA (1) EA020589B1 (sr)
ES (4) ES2745479T3 (sr)
FI (2) FI4159217T3 (sr)
HR (3) HRP20260236T1 (sr)
HU (3) HUE060206T2 (sr)
IL (1) IL219073A (sr)
LT (4) LT2488033T (sr)
MA (1) MA33746B1 (sr)
ME (1) ME03497B (sr)
MX (1) MX2012004413A (sr)
MY (1) MY174759A (sr)
NZ (1) NZ598913A (sr)
PE (1) PE20121093A1 (sr)
PH (1) PH12012500742A1 (sr)
PL (4) PL4159217T3 (sr)
PT (4) PT4397376T (sr)
RS (4) RS59181B1 (sr)
SI (3) SI4397376T1 (sr)
UA (1) UA105064C2 (sr)
WO (1) WO2011047238A1 (sr)
ZA (1) ZA201202612B (sr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2303021T3 (en) 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
EP2545187B1 (en) * 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
EP2635286A4 (en) * 2010-11-05 2014-11-12 Glaxosmithkline Ip No 2 Ltd METHOD FOR THE TREATMENT OF CANCER
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
KR20140107576A (ko) * 2011-12-22 2014-09-04 글락소스미스클라인 엘엘씨 Braf 저해제 및/또는 mek 저해제와 magea3 면역치료제를 이용한 암 치료 방법
EP2830664A1 (en) * 2012-03-30 2015-02-04 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
HRP20211817T1 (hr) * 2012-09-04 2022-03-04 Novartis Ag Postupak adjuvantnog liječenja raka
BR112015009134A2 (pt) * 2012-10-25 2017-07-04 Glaxosmithkline Llc combinação
MA38121A1 (fr) * 2012-11-30 2016-10-31 Glaxosmithkline Llc Nouvelle composition pharmaceutique
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
CN105658206A (zh) * 2013-06-03 2016-06-08 诺华股份有限公司 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
MX2016007653A (es) * 2013-12-12 2016-10-13 Novartis Ag Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.
ES2660989T3 (es) 2013-12-28 2018-03-27 Guardant Health, Inc. Métodos y sistemas para detectar variantes genéticas
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
RU2733393C9 (ru) 2014-05-06 2021-09-09 Джи Ти Икс, ИНК. Соединения для лечения рака
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN110022878A (zh) * 2016-11-03 2019-07-16 密执安大学评议会 Egfr/pi3k的小分子双重抑制剂及其用途
WO2020079581A1 (en) 2018-10-16 2020-04-23 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN112294965B (zh) * 2019-07-26 2023-03-14 苏州亚盛药业有限公司 Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
WO2023081676A1 (en) * 2021-11-02 2023-05-11 Verastem, Inc. Methods of treating abnormal cell growth
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
PT2298768E (pt) * 2004-06-11 2012-12-05 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CA2924418A1 (en) 2007-07-30 2009-02-05 Jean-Michel Vernier Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
DK3560498T3 (da) 2022-11-14
EP4397376A3 (en) 2024-10-30
FI4159217T3 (fi) 2024-08-15
LT2488033T (lt) 2019-09-10
CN102655753B (zh) 2015-11-25
ZA201202612B (en) 2013-09-25
ME03497B (me) 2020-04-20
EP3560498A1 (en) 2019-10-30
JP2013508294A (ja) 2013-03-07
WO2011047238A1 (en) 2011-04-21
AU2010306653B2 (en) 2013-10-24
ES2986037T3 (es) 2024-11-08
EP4397376B1 (en) 2025-11-26
ES2745479T3 (es) 2020-03-02
EP2488033A1 (en) 2012-08-22
PH12012500742A1 (en) 2015-12-11
PE20121093A1 (es) 2012-09-04
CO6531498A2 (es) 2012-09-28
EP4159217A1 (en) 2023-04-05
EP4706770A2 (en) 2026-03-11
RS63702B1 (sr) 2022-11-30
KR101729116B9 (ko) 2026-02-05
SI4397376T1 (sl) 2026-04-30
CN102655753A (zh) 2012-09-05
HRP20260236T1 (hr) 2026-04-10
RS59181B1 (sr) 2019-10-31
LT4397376T (lt) 2026-03-10
US8952018B2 (en) 2015-02-10
LT3560498T (lt) 2022-11-25
PL2488033T3 (pl) 2019-12-31
EA020589B1 (ru) 2014-12-30
HRP20221304T1 (hr) 2022-12-23
CY1122013T1 (el) 2020-10-14
CA2775803C (en) 2017-11-21
CL2012000964A1 (es) 2012-08-31
DK4397376T3 (da) 2026-02-23
HUE067723T2 (hu) 2024-11-28
JP5718929B2 (ja) 2015-05-13
KR101729116B1 (ko) 2017-05-02
US20150111904A1 (en) 2015-04-23
MX2012004413A (es) 2012-05-08
AU2010306653A1 (en) 2012-05-10
CA2775803A1 (en) 2011-04-21
EP3560498B1 (en) 2022-08-17
SI2488033T1 (sl) 2019-10-30
MA33746B1 (fr) 2012-11-01
DOP2012000091A (es) 2013-09-15
US20120196879A1 (en) 2012-08-02
EP4397376A2 (en) 2024-07-10
PT4159217T (pt) 2024-08-12
DK4159217T3 (da) 2024-08-12
BR112012008854A2 (pt) 2015-09-22
PL4159217T3 (pl) 2024-09-30
EP4159217B1 (en) 2024-05-22
KR20120104547A (ko) 2012-09-21
PT2488033T (pt) 2019-09-10
EP2488033B1 (en) 2019-06-12
FI4397376T3 (fi) 2026-02-24
ES3063926T3 (en) 2026-04-21
UA105064C2 (uk) 2014-04-10
PT3560498T (pt) 2022-11-03
RS65800B1 (sr) 2024-08-30
US8703781B2 (en) 2014-04-22
EA201290149A1 (ru) 2012-11-30
EP2488033A4 (en) 2014-04-30
PL4397376T3 (pl) 2026-03-30
MY174759A (en) 2020-05-13
PL3560498T3 (pl) 2022-12-12
IL219073A (en) 2016-05-31
SI4159217T1 (sl) 2024-09-30
ES2930157T3 (es) 2022-12-07
BR112012008854B8 (pt) 2021-05-25
IL219073A0 (en) 2012-06-28
DK2488033T3 (da) 2019-09-02
NZ598913A (en) 2013-11-29
US20140187566A1 (en) 2014-07-03
HRP20191617T1 (hr) 2019-12-13
BR112012008854B1 (pt) 2020-12-29
LT4159217T (lt) 2024-08-26
HUE060206T2 (hu) 2023-02-28
HUE046139T2 (hu) 2020-02-28
CR20120155A (es) 2012-07-05
PT4397376T (pt) 2026-02-24

Similar Documents

Publication Publication Date Title
HUE060206T2 (hu) MEK gátlót és B-Raf gátlót tartalmazó kombináció
ZA201202618B (en) Combinations of a p13k inhibitor and a mek inhibitor
PL2328784T3 (pl) Połączenie ramienia wycieraczki z piórem wycieraczki oraz pióro wycieraczki
ZA201204700B (en) Optimized endonucleases and uses thereof
GB2469720B (en) Join-us call-log and call-answer messages
IL214403A0 (en) Novelcell lines and methods
IL217761A0 (en) Dilator and assembly comprising such a dilator
EP2517684A4 (en) AIRWAY OPENING TOOL AND AIRWAY OPENING UNIT THEREWITH
GB0908280D0 (en) Trackbed liner and related methods
GB2473864B (en) Improved mouthguard and tool
GB0901207D0 (en) Chelating agents and methods relating thereto
IL210767A (en) Head missile and matching missile
GB0912744D0 (en) Methods and uses
GB0909380D0 (en) Method and use
TWM374132U (en) Hard disk fixing device and electronic device
MTP4272B (en) Ssi - cement and jablo board
GB0916070D0 (en) Power and data unit
GB0920904D0 (en) Uses and methods
IL216594A0 (en) Proteasome inhibitors and uses thereof
HUP0800405A2 (en) Environment-friendly biocidis and use thereof
TWM370636U (en) Key blank and key
GB0918131D0 (en) Threshold construction and component therefor